New York Times reporters Jonathan Corum and Matt Richtel have an excellent article in today’s edition reporting on “The Fast-Changing Chemistry of New, Dangerous Drugs.”
The piece describes how the illicit drug market has evolved from plant-based substances to highly potent synthetic drugs manufactured in small, often makeshift laboratories. In these settings, chemists can modify molecular structures to create ever-stronger variants that are easier to conceal and transport. These decentralized operations—sometimes little more than kitchen-scale setups—enable producers to stay ahead of law enforcement while saturating the market with unpredictable, ultra-potent products.
The article also includes especially clear, accessible illustrations of the molecules themselves, helping readers without a background in organic chemistry understand how easily illicit innovators can modify chemical structures to create new drugs.
The result is a drug supply that is not only stronger but also far more variable and opaque, increasing risks for people who use drugs because they cannot reliably know what they are getting or how potent it is. This dynamic continues to drive overdose rates in ways that prohibition has consistently failed to control.
The New York Times piece skillfully demonstrates the “iron law of prohibition” in action—the harder the enforcement, the harder the drugs. I have discussed the iron law here, here, and here; explained it to members of the House Judiciary Committee here; and Leo Beletsky and Corey S. Davis, years ago, explained how fentanyl emerged in the underground market as an illustration of this phenomenon.
The implication is straightforward but often overlooked by policymakers and the press: Tougher enforcement does not eliminate drug use; it pushes the market in more dangerous directions. When authorities crack down on bulkier, less potent substances, suppliers logically shift to more compact, highly potent alternatives that are easier to produce, hide, and transport.
That is how we moved from diverted prescription pain pills to heroin, from heroin to fentanyl, and now to ever-more powerful synthetic analogs. Each escalation is not a failure of enforcement—it is its predictable result. As long as prohibition persists, the incentive structure will reward potency and unpredictability, driving the market toward substances that are deadlier per gram and harder to regulate informally. And beyond being an assault on adult autonomy, as I discuss in my book Your Body, Your Health Care, the war on drugs is ultimately a war on people, because people are the ones who bear the risks created by a policy that makes the drug supply progressively more dangerous.
In their article, the Times authors don’t mention the iron law of prohibition, but a companion piece they link to offers an illuminating inside look at a drug trafficker’s workshop. It shows how producers systematically experiment with chemical formulas, swap ingredients based on availability, and rapidly adjust potency and composition to evade law enforcement while maximizing efficiency and profit. This glimpse into the daily reality of illicit production underscores how adaptable and innovative these operations are: When one substance or precursor becomes scarce or risky, producers simply pivot to another, often creating even more potent and unpredictable compounds in the process. In other words, the behavior on display in that workshop is not aberrational; it is exactly what prohibition incentivizes.
The lesson here isn’t complicated, even if the chemistry is. Policies that push drug use underground don’t make it disappear—they make it more dangerous. Until that reality sinks in, the cycle the Times so vividly documents will continue, with real people paying the price.
